Replies to post #30681 on Applied DNA Sciences Inc (APDN)

[apdn1mill]

I usually don't trust his ratings. So outperform also doesn't matter to me. He kept on changing the 2014 revenue.

[Shail]

I agree with you. Zacks has been consistently changing their ratings over the past few years and always pushing out the year of profitability with every new rating.

Basically all these analysts are the same. At least he is not giving a negative rating which could harm us further. In any case the results have been disappointing.

[apdn1mill]

Also,
I dont see this on earnings report. This is what Zacks said.

As of March31, 2014, Applied DNA had $2.0 in cash. According to our model, the Company s current
cash balance along with its current customer base, projected cash flow and the minimum projected
revenues for this remaining fiscal year will allow the company to have sufficient capital resources to meet
projected cash flow requirements for the next twelve months.

This is what I found on earnings report.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of March 31, 2014, we had working capital of $967,081. For the six months ended March 31, 2014, we generated a net cash flow deficit from operating activities of $4,262,536 consisting primarily of our loss of $9,042,086, net with non-cash adjustments of $212,025 in depreciation and amortization charges, $1,313,331 for equity based compensation, $2,178,859 change in fair value of warrant liability, $337,500 in common stock issued for consulting services and $16,144 of bad debt expense. Additionally, we had a net decrease in operating assets of $109,633 and a net increase in operating liabilities of $612,058. Cash used in investing activities was $109,581 for the purchase of property, plant and equipment. There were no financing activities during the six months ended March 31, 2014.

The Company has recurring net losses, which have resulted in an accumulated deficit of $195,735,697 as of March 31, 2014. The Company incurred a net loss of $9,042,086 and generated negative operating cash flow of $4,262,536 for the six month period ended March 31, 2014. However, the Company has attained positive working capital of $967,081 as of March 31, 2014. At March 31, 2014, the Company had cash and cash equivalents of $1,988,184. The Company’s current capital resources include cash and cash equivalents and other working capital resources, and cash generated through operations. Historically, the Company has financed its operations principally from the sale of equity securities.

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company attaining profitable operations. The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional financing, it will most likely be forced to reduce operations.

Management believes that it will be able to raise additional funds and the Company is currently in discussions with investment bankers and potential investors regarding possible financing. However, the Company has no formal commitments for any future funding, and may not be able to obtain additional financing on terms acceptable to it, if at all, in the future.

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty